Chemotherapy: New FluCam combination therapy has familiar limitations

Nat Rev Clin Oncol. 2011 Dec 6;9(1):14-5. doi: 10.1038/nrclinonc.2011.191.
No abstract available

Publication types

  • News

MeSH terms

  • Alemtuzumab
  • Antibodies, Monoclonal, Humanized / administration & dosage*
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Antibodies, Monoclonal, Murine-Derived / administration & dosage
  • Antibodies, Monoclonal, Murine-Derived / therapeutic use
  • Antigens, CD
  • Antigens, Neoplasm
  • Antineoplastic Agents / therapeutic use*
  • CD52 Antigen
  • Cyclophosphamide / administration & dosage
  • Cyclophosphamide / therapeutic use
  • Drug Therapy, Combination
  • Glycoproteins
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
  • Rituximab
  • Vidarabine / administration & dosage
  • Vidarabine / analogs & derivatives*
  • Vidarabine / therapeutic use

Substances

  • Antibodies, Monoclonal, Humanized
  • Antibodies, Monoclonal, Murine-Derived
  • Antigens, CD
  • Antigens, Neoplasm
  • Antineoplastic Agents
  • CD52 Antigen
  • CD52 protein, human
  • Glycoproteins
  • Alemtuzumab
  • Rituximab
  • Cyclophosphamide
  • Vidarabine
  • fludarabine